This is $200 million compared to Merck & Co., Ltd.

Takeda Pharmaceutical, one person, even gave an exaggerated price of $300 million.

Although Abel knew that the [Little Blue Pill] money was definitely more than this price. But when I thought that I had only copied for a month and been an experimental dog for a month, I would have earned hundreds of millions of dollars.

Harvesting huge wealth, huge money, the excitement in his heart, words are indescribable.

It's just that the small wrecking ball floating in front of him reminds him that he is actually in control of the most terrifying gold mine in the world.

Thirty years ahead, almost limitless knowledge.

He is the only person in this world who is cursed by knowledge.

He took a deep breath.

There is another unbid next to him, the future No. 1 pharmaceutical company in the universe, and the future chairman of Pfizer is still next to him.

Abel looked at William Jr. C. Stehr, a little excited, said, "Mr. Stehl." Merck and Takeda have both given prices, and I'd like to hear Pfizer's opinion. ”

William Jr. C. Stehr doesn't seem to be anxious about the attractive prices offered by Merck and Takeda.

He gave his price very calmly:

"$200 million! Cash! Please forgive Pfizer for only coming up with this cash at the moment, our sales were only $5.9 billion last year, and our net profit was only $500 million. Coming up with $200 million at one time is a lot of sincerity on our part!"

He was not lying about it.

The current Pfizer is not the No. 1 pharmaceutical company in the universe in the future. It can't compare to the strength of Merck, the world's second pharmaceutical company, and it can't compare to Takeda Pharmaceutical, which has the support of a chaebol behind it.

The current Pfizer is just a second-tier large American pharmaceutical company. With the current scale of Pfizer, it is hard to imagine that in 10 years, it will suddenly become one of the world's top three pharmaceutical companies with a small blue pill.

Being able to take about half of last year's profits to buy the research results of an unknown young man is very sincere for a second-tier pharmaceutical company like Pfizer.

But Abel was a little disappointed.

$200 million, the same price as Merck. If that's just the price, why wouldn't he work with Merck?

The current Pfizer is no match for Merck.

Not to mention Takeda Pharmaceutical, which has bid $300 million.

As for if the little blue pill is not sold to Pfizer, Pfizer may not be able to become the No. 1 pharmaceutical company in the universe in the future, what does this have to do with Abel?

He's not a philanthropist.

Abel raised an eyebrow.

I want to talk to a person, and I can sell it to a person for $300 million, but I can go to work in a book.

He has no affection for this country, except for some kind of action movie and those young and beautiful female stars.

William Jr. C. Stehl suddenly and quickly added:

"In addition to $200 million in cash! Pfizer is also willing to give 10% of the future sales of this drug as Mr. Sephorosa's share! That is, the price of Pfizer is $200 million + 10% of the sales share!"

These words of his.

All of a sudden, the two representatives of Takeda Pharmaceutical and Merck opened their eyes wide.

$200 million is easy to understand, if this drug really has this effect, $1 billion is actually willing to be taken out. But 10% of the sales share, that's a big deal! It's a sales share, not a profit share!

The sales share means that if the drug sells 10 billion a year in the future, Abel will be able to get 10% - 1 billion US dollars!

In terms of profit sharing, it is necessary to deduct pharmaceutical costs, publicity, channel expenses, public relations expenses, etc., and then calculate the profit, of course, it is not as high as the sales share.

The representative of Takeda Pharmaceutical secretly screamed in his heart, he had just contacted the headquarters. The price given to him by the headquarters is actually as high as 500 million US dollars, provided that the drug really has this effect, and a gambling agreement must be signed - gambling that the drug can be marketed normally, and the sales in the first three years must be more than 2 billion US dollars.

As a rising generation of the world's major pharmaceutical companies, Takeda Pharmaceutical has always had the ambition to go to the world, backed by many chaebols.

Takeda is just missing some of its flagship products.

[Sildenafil Citrate] is a male miracle drug, as a medical research expert of one person.

Representatives of Takeda Pharmaceutical Company are deeply aware that in the modern society, the number of men ED formed by work pressure is terrifying!

If we get this kind of drug, even if we don't go to the international market so quickly, just selling a copy of the domestic market can make Takeda Pharmaceutical make a lot of money.

After hearing about Merck's $200 million offer, he already felt secure. Thinking of saving some money for the company, the offer of 500 million was pressed into 300 million.

I didn't expect Pfizer's William Jr. C. Stell, however, gave a price of $200 million + 10% of the sales share.

All of a sudden, the representatives of Takeda Pharmaceutical were confused.

Representatives of Merck & Co. were also in a hurry.

Merck's headquarters only gave him a price of $200 million, and he didn't know how to respond to Takeda's offer just now.

I didn't expect Pfizer to be more ruthless.

In addition to cash, there is also a 10% share of sales! Let him take the lead to negotiate? He complained in his heart, this little devil and Pfizer are so optimistic about this kind of [sildenafil citrate]?

Although it has reached the fifth step of the FDA review, isn't it still not passed after all? There is still a possibility of failing the review, is it necessary to bid so ruthlessly?

As a representative of the world's second-largest pharmaceutical company, of course, he does not appreciate the enterprising spirit of Takeda Pharmaceutical, as well as Pfizer, a pharmaceutical company of the world's second-tier brands.

The two representatives looked at Abel with anxious expressions, they didn't want Abel to agree.

The representative of Takeda Pharmaceutical hurriedly said anxiously, "Mr. Sephorosa! 500 million US dollars! Takeda Pharmaceutical is willing to contribute 500 million US dollars, and it is all cash!"

Even the representative of Merck, who actually couldn't give a better price, hurriedly said:

"$200 million is not going to be Merck's bottom line. Mr. Sephorosa, please come with me to the company's headquarters. I believe that Merck will give you a better price because we are the world's number one pharmaceutical company!"

But after listening to Pfizer's bid, Abel no longer considered Yiyi and Merck.

If it was an obscure small company in the "original script", even if the other party's sales were 50%, he would not be tempted.

Now this condition is given, but the future chairman of the universe No. 1 Pharmaceutical Company! What's more, Abel knows deeply that as long as Pfizer gets [sildenafil citrate], it is very likely that it will still be like in the "original script".

In 10 years, it will become the top 3 in the world, and in 20 years it will become the first in the world!

He no longer looked at Merck's representative and himself, and went straight to William Jr. C. St. Sterdoor:

"20% of the sales share! 10 years of share, 10 years of automatic relinquishment of patent shares. By the way, the one-time cash mention is $300 million. ”

That's bargaining.

Internationally, the validity period of new drug patents is generally about 20 years. However, the United States and a certain patent can be extended, generally not more than 5 years.

After the expiration of the patent, as long as it is a qualified pharmaceutical factory, as long as it can produce it, it can produce this drug.

For example, in the "original script", Pfizer's little blue pill was just launched in 1998. After 2000, he officially entered Huaxia and obtained his own new drug patent. After 2010, Huaxia's patent expired.

It is only in China that various domestic Ge and Ge similar drugs have appeared.

Of course.

The little blue pill is just the world's first ED treatment, not the only one.

In the "original script", there will be other "phosphodiesterase 5 (PDE5) inhibitors" in the world in the future - this is the academic name for this type of drug.

Many of the drugs used for general treatment are called "xxxxx inhibitors" in academic terms.

For example, omeprazole, which was launched in 1988, quickly became one of the most popular gastrointestinal drugs in the world, and the name of this drug in the academic community is "proton pump inhibitor".

There are three similar "PDE5 inhibitors" that will be marketed in the future, namely Pfizer's Viagra (sildenafil), Eli Lilly's Cialis (tadanafil) and Bayer's levitra (vardenafil), in addition, ED drugs include Bifar of Nicky Company in the United States, Ixense of Takeda Company, etc.

All of them sold very well.

In addition to sildenafil, a second similar drug did not appear until 1999. Excluding the spoiler Abel, Pfizer now gets this drug, which can be sold exclusively for at least 9 years.

Gee...... Near-monopoly profits, Abel doesn't think they'll lose money. As for the addition of other new drugs after 1999, they have made a monopoly for 9 years, and it is time for others to make some money!

Abel's proposal of a 20% sales share for 10 years is aimed at this. In 10 years, if other drugs appear, profits will definitely decline under the competition. 10 years later, he probably doesn't need a drug to make money.

Earn ten years hard.

That's what Abel had in mind.

It's just a 20% share of sales, which is a bit high. Although most of the cost of new drugs is in research and development, the cost of manufacturing is very low. The cost of a new drug is 10 yuan, at least 6 yuan is in research and development, and the remaining 4 yuan includes pharmaceutical costs, publicity costs, channel fees and other miscellaneous expenses.

In the next year, if the annual sales are 2 billion US dollars, the cost of pharmaceuticals, publicity and distribution may only be about 600 million US dollars, and the rest is profit.

That's right, the profits of drugs are so terrible! Otherwise, pharmaceutical companies would not be among the most profitable companies in the world.

If 2 billion US dollars in sales are divided into 20%, Abel can share 400 million US dollars a year. After deducting the cost, Pfizer still makes money, and it makes a lot of money.

This is where William Jr. C. Stehl clearly knew very well, and he thought quickly and made a decision almost in a matter of seconds.

In the next 20 years, he will lead Pfizer to become the manager of the No. 1 pharmaceutical company in the universe, and he can't wait to reach out:

"Deal!"